• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Traws Pharma Inc.

    11/14/25 2:29:27 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRAW alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Traws Pharma, Inc.

    (Name of Issuer)


    Common Stock, par value $.01 per share

    (Title of Class of Securities)


    68232V884

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68232V884


    1Names of Reporting Persons

    Squadron Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    523,359.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    523,359.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    523,359.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    68232V884


    1Names of Reporting Persons

    Squadron Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    591,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    591,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    591,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    68232V884


    1Names of Reporting Persons

    Matthew Sesterhenn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    591,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    591,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    591,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    68232V884


    1Names of Reporting Persons

    William Blank
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    591,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    591,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    591,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Traws Pharma, Inc.
    (b)Address of issuer's principal executive offices:

    12 PENNS TRAIL, NEWTOWN, PENNSYLVANIA, 18940.
    Item 2. 
    (a)Name of person filing:

    Squadron Master Fund LP Squadron Capital Management, LLC Matthew Sesterhenn William Blank
    (b)Address or principal business office or, if none, residence:

    Squadron Master Fund LP c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 Matthew Sesterhenn c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559 William Blank c/o Squadron Capital Management, LLC 999 Oakmont Plaza Drive, Suite 600 Westmont, IL 60559
    (c)Citizenship:

    Squadron Master Fund LP - Delaware Squadron Capital Management, LLC - Delaware Matthew Sesterhenn - United States William Blank - United States
    (d)Title of class of securities:

    Common Stock, par value $.01 per share
    (e)CUSIP No.:

    68232V884
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Squadron Capital Management, LLC is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein. Squadron Master Fund LP - 523,359 shares Squadron Capital Management, LLC - 591,000 shares Matthew Sesterhenn - 591,000 shares William Blank - 591,000 shares
    (b)Percent of class:

    Ownership percentage is based on 7,063,829 shares of common stock, par value $0.01 per share, outstanding as of August 12, 2025, as represented by the Issuer in the Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025. Squadron Master Fund LP - 7.4% Squadron Capital Management, LLC - 8.4% Matthew Sesterhenn - 8.4% William Blank - 8.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Squadron Master Fund LP - 0 Squadron Capital Management, LLC - 0 Matthew Sesterhenn - 0 William Blank - 0

     (ii) Shared power to vote or to direct the vote:

    Squadron Master Fund LP - 523,359 shares Squadron Capital Management, LLC - 591,000 shares Matthew Sesterhenn - 591,000 shares William Blank - 591,000 shares

     (iii) Sole power to dispose or to direct the disposition of:

    Squadron Master Fund LP - 0 Squadron Capital Management, LLC - 0 Matthew Sesterhenn - 0 William Blank - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Squadron Master Fund LP - 523,359 shares Squadron Capital Management, LLC - 591,000 shares Matthew Sesterhenn - 591,000 shares William Blank - 591,000 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Notes above.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Squadron Master Fund LP
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Partner, Squadron Partners LLC, its General Partner
    Date:11/14/2025
     
    Squadron Capital Management LLC
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Partner
    Date:11/14/2025
     
    Matthew Sesterhenn
     
    Signature:/s/ Matthew Sesterhenn
    Name/Title:Matthew Sesterhenn
    Date:11/14/2025
     
    William Blank
     
    Signature:/s/ William Blank
    Name/Title:William Blank
    Date:11/14/2025
    Get the next $TRAW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRAW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRAW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

    Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs.

    11/13/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

    SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ:TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025. Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibito

    10/30/25 12:00:00 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

    DOVER, Del., Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ:TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients. Expert Systems' predictive pharmacology and AI-driven molecular modeling played a central role in Ratutrelvir's differentiation—optimizing pharmacokinetics, safety, and potency profiles to ensure broad clinical applicability across both therapeutic and preven

    10/22/25 6:40:00 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Traws Pharma Inc.

    SCHEDULE 13G/A - Traws Pharma, Inc. (0001130598) (Subject)

    11/14/25 4:00:03 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Traws Pharma Inc.

    SCHEDULE 13G/A - Traws Pharma, Inc. (0001130598) (Subject)

    11/14/25 2:29:27 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Traws Pharma Inc.

    10-Q - Traws Pharma, Inc. (0001130598) (Filer)

    11/13/25 7:30:26 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Savchuk Nikolay

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    10/15/25 8:10:29 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Redfield Robert

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    10/15/25 8:09:39 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Science Officer Virology Pauza Charles David

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    10/15/25 8:08:46 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Leadership Updates

    Live Leadership Updates

    View All

    Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

    Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs.

    11/13/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

    NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws' Board of Directors (the "Board") has eliminated the interim notation of its key executives Iain Dukes and Charles Parker, who are now Chief Executive Officer and Chief Financial Officer, respectively. "Dr. Leaman brings more than a decade of experience in finance, M&A and

    10/6/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Traws Pharma Inc.

    SC 13D/A - Traws Pharma, Inc. (0001130598) (Subject)

    11/6/24 4:12:57 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Traws Pharma Inc.

    SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

    9/23/24 6:44:56 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Financials

    Live finance-specific insights

    View All

    Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

    Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoing infection risk and greater need, with waning vaccine utilization A submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir in newly diagnosed COVID patients, with extensions to assess rebound and Long COVID, as well as evaluation in PAXLOVID®-ineligible subjects TXM program to emphasize focus on stockpiling readiness Traws to host a Q2 2025 business upda

    8/14/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information Date: Thursday, August 14, 2025, at 8:30 AM ETParticipant Dial-in (U.S.): 1-877-407-0789Participant Dial-in (International): 1-201-689-8562Conference ID: 13754425Webcast Access: Cl

    8/8/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

    Merger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond Lead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in the Phase 1 dose extension study in AustraliaCOVID-19 program, ratutrelvir, completed the Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) study in Australia Oncology strategy includes investigator-sponsored trials (ISTs), planned to begin in H2 2024, adding a new

    8/15/24 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care